Importantly, disruption of GHR-JAK2-STAT5 signaling is associated with hepatic metabolic changes that include fatty liver, fibrosis, and hepatocellular carcinoma (Baik et al., 2011). Here, STAT5A is linked to Hepatic steatosis.